TL;DR
Restaurant chains are adding smaller portions and higher-protein options as GLP-1 drug users eat less and eat differently — the menu is now a pharmaceutical side effect.
MSM Perspective
The Wall Street Journal covered the menu changes as a restaurant industry trend piece.
X Perspective
X's food and health communities are debating whether Ozempic is doing more for American diets than any government nutrition program ever did.
At least twelve major restaurant chains have introduced smaller portion sizes, higher-protein options, or dedicated "right-sized" menu sections in the first quarter of 2026, according to Nation's Restaurant News. Applebee's added four entrees under 500 calories. Darden Restaurants (Olive Garden, LongHorn) launched a protein-focused menu. Chili's reduced average portion sizes by 15 percent across its core menu. [1]
The catalyst is GLP-1 receptor agonist drugs — Ozempic, Wegovy, Mounjaro — which reduce appetite and change food preferences. An estimated 9 million Americans are now taking GLP-1 drugs. The pharmaceutical industry is reshaping the restaurant industry.
-- NORA WHITFIELD, Chicago